Pieris Pharmaceuticals GmbH
🇩🇪Germany
Clinical Trials
6
Active:2
Completed:3
Trial Phases
1 Phases
Phase 1:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (100.0%)Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Phase 1
Completed
- Conditions
- Anemia of Chronic Kidney Disease
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Pieris Pharmaceuticals GmbH
- Target Recruit Count
- 11
- Registration Number
- NCT03325621
- Locations
- 🇨🇿
University Hospital Brno, Brno, Czechia
🇨🇿HDS - Klaudian's Hospital, Mladá Boleslav, Czechia
🇨🇿Institute of Clinical and Experimental Medicine (ICEM), Prague, Czechia
Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Phase 1
- Conditions
- Anemia of Chronic Kidney Disease
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Pieris Pharmaceuticals GmbH
- Target Recruit Count
- 24
- Registration Number
- NCT02754167
- Locations
- 🇩🇪
St. Joseph Krankenhaus, Berlin, Germany
🇩🇪Technical University, Medical Department, Munich, Germany
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Pieris Pharmaceuticals GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT02340572
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- Drug: Angiocal® (PRS-050-PEG40)
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2011-10-19
- Lead Sponsor
- Pieris Pharmaceuticals GmbH
- Target Recruit Count
- 26
- Registration Number
- NCT01141257
News
No news found